Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis

Khorramnia, Saeed; Navidi, Zia; Orandi, Amirhossein; Iravani, Mojgan Mohajeri; Orandi, Amirali; Malekabad, Ebadallah Shiri; Moghadam, Seyed Hamid Pakzad

doi:10.4285/ctr.24.0015

Clin Transplant Res

2024

DOI: 10.4285/ctr.24.0015

|View full text |Cite

Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis

Saeed Khorramnia,

Zia Navidi,

Amirhossein Orandi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Navidi,

Pakzad Moghadam,

Iravani

et al. 2024

Clin Transplant Res

View full text Add to dashboard Cite

Background The use of remdesivir in solid organ transplant recipients (SOTRs) with coronavirus disease 2019 (COVID-19) has been studied. The present systematic review and analysis aimed to assess its effectiveness in this population. Methods A comprehensive search of PubMed, Cochrane Library, Web of Science, Embase, medRxiv, and Google Scholar was conducted to identify relevant articles published up to April 2024. The quality of the included studies was evaluated using the Cochrane assessment tool. Data analysis was performed using the Comprehensive Meta-Analysis software ver. 3.0. Results The meta-analysis included seven eligible retrospective studies, involving a total of 574 SOTRs. The findings indicated no significant differences in mortality rate (odds ratio [OR], 1.19; 95% confidence interval [CI], 0.59–2.39), hospitalization rate (OR, 0.69; 95% CI, 0.10–4.79), need for mechanical ventilation (OR, 0.98; 95% CI, 0.44–2.18), or need for oxygen therapy (OR, 3.73; 95% CI, 0.75–18.34) between the groups that received remdesivir and those that did not. However, a statistically significant difference was observed in the rate of intensive care unit admissions between the two groups (OR, 2.39; 95% CI, 1.24–4.57). Conclusions Our meta-analysis found that remdesivir offers no clinical benefits to SOTRs infected with COVID-19. Additional high-quality research is required to assess the potential clinical advantages of remdesivir for SOTRs with COVID-19.

show abstract

Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Navidi,

Pakzad Moghadam,

Iravani

et al. 2024

Clin Transplant Res

View full text Add to dashboard Cite

show abstract

Comparing the Effectiveness and Safety of Casirivimab/Imdevimab With Bamlanivimab in Patients With Covid-19: A Systematic Review and Meta-Analysis

Karimi Babaahmadi,

Mohajeri Iravani,

Orandi

et al. 2024

Studies in Medical Sciences

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis

Cited by 2 publications

References 29 publications

Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

Comparing the Effectiveness and Safety of Casirivimab/Imdevimab With Bamlanivimab in Patients With Covid-19: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About